Stock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut

Stock Track

05/01

Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.

The company's upsized initial public offering was priced at $18 per share, at the top end of the expected $16 to $18 range, raising $300 million. Avalyn increased the offering size from 11.8 million to 16.7 million shares, indicating strong investor demand for the IPO.

Proceeds from the offering will fund late-stage clinical studies for Avalyn's pipeline of inhaled therapeutics for rare respiratory diseases, including its lead candidates AP01 and AP02. The company's successful IPO pricing and trading debut reflect investor confidence in its clinical programs and market potential.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1133662273"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133662273\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133662273?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133662273","market":"us","top_or_hot":-1,"title":"Stock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut","media":"Stock Track","content":"<p>Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.</p><p>The company's upsized initial public offering was priced at $18 per share, at the top end of the expected $16 to $18 range, raising $300 million. Avalyn increased the offering size from 11.8 million to 16.7 million shares, indicating strong investor demand for the IPO.</p><p>Proceeds from the offering will fund late-stage clinical studies for Avalyn's pipeline of inhaled therapeutics for rare respiratory diseases, including its lead candidates AP01 and AP02. The company's successful IPO pricing and trading debut reflect investor confidence in its clinical programs and market potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avalyn Pharma Soars 44.44% in Intraday Trading on Nasdaq IPO Debut\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-01 01:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.</p><p>The company's upsized initial public offering was priced at $18 per share, at the top end of the expected $16 to $18 range, raising $300 million. Avalyn increased the offering size from 11.8 million to 16.7 million shares, indicating strong investor demand for the IPO.</p><p>Proceeds from the offering will fund late-stage clinical studies for Avalyn's pipeline of inhaled therapeutics for rare respiratory diseases, including its lead candidates AP01 and AP02. The company's successful IPO pricing and trading debut reflect investor confidence in its clinical programs and market potential.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVLN","symbol_name":"Avalyn Pharma","start_time":0,"source_url":"","article_id":"1133662273","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133662273","pubTimestamp":1777570002,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.The company's upsized...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVLN":"Avalyn Pharma"},"translate_title":"股票追踪|Avalyn Pharma纳斯达克IPO首秀盘中大涨44.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVLN":1},"content_text":"Avalyn Pharma's stock soared 44.44% in intraday trading on Thursday as the clinical-stage biopharmaceutical company made its trading debut on the Nasdaq Global Select Market.The company's upsized initial public offering was priced at $18 per share, at the top end of the expected $16 to $18 range, raising $300 million. Avalyn increased the offering size from 11.8 million to 16.7 million shares, indicating strong investor demand for the IPO.Proceeds from the offering will fund late-stage clinical studies for Avalyn's pipeline of inhaled therapeutics for rare respiratory diseases, including its lead candidates AP01 and AP02. The company's successful IPO pricing and trading debut reflect investor confidence in its clinical programs and market potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}